BioHealth Innovation Weekly for May 21, 2024

Trouble Viewing This Email: Click Here

May 21, 2024

Save the Dates: 2024 BioHealth Capital Region Week Registration Coming Soon

Looking forward to the Autumn of 2024, the BioHealth Capital Region is gearing up for three major events, September 17th, 18th, and 19^th, 2024, that promise to bring together industry leaders, investors, and innovators from across the biopharma and healthcare sectors. Whether you're a company seeking investment, an entrepreneur ready to showcase your innovations, or an industry professional looking to network and gain insights, these events are not to be missed. Mark your calendars and stay tuned as registration and application sites will be going live soon.

10th Annual BioHealth Capital Region Forum

Dates: September 17-18, 2024
Venue: US Pharmacopeia, Rockville, MD

Celebrate a decade of achievements and advancements at the 10th Annual BioHealth Capital Region Forum. This milestone event will reflect on ten years of progress within the BioHealth sector and set the stage for future innovations. Attendees will have the opportunity to engage in meaningful discussions, participate in networking sessions, and connect with hundreds of C-level executives from government, academia, and industry. If you're looking to stay on the cutting edge of biopharma developments, this is the place to be.

Explore a Career in Life Sciences Business Strategy with BioHealth Innovation, Inc.

Are you a recent PhD graduate eager to blend your scientific expertise with business acumen? BioHealth Innovation, Inc. (BHI) is looking for an Entry-Level Life Sciences Business Strategist to join their team. This remote opportunity is ideal for early-career scientists passionate about accelerating the adoption of new technologies to improve lives.

What Will You Do? As a Business Strategist at BHI, you'll support growth-stage businesses by developing commercialization plans and crafting federal grant proposals. You'll also engage with expert Entrepreneurs-In-Residence and other professionals, fostering relationships that drive the commercial potential of emerging technologies in fields like therapeutics and medical devices.

Who Should Apply? If you hold a Ph.D. in biological sciences and have strong writing and analytical skills, you might be the perfect candidate. We're looking for driven individuals who are adept at managing multiple projects and keen on making a significant impact in the biohealth industry.

Why BHI? Joining BHI means you'll be part of a team dedicated to growing the BioHealth Capital Region through innovative commercialization strategies. This position offers a unique chance to develop your career at the intersection of science and business, engaging with key stakeholders across the industry.

Interested in making a difference in the biohealth sector? Learn more about this exciting opportunity and how to apply by clicking here. Join BHI and help shape the future of BioHealth.

Baltimore Fishbowl: MCB Real Estate announces plans for a mixed-use development in Montgomery County that will have a focus on the life sciences and biohealth

MCB Real Estate, the developer of Harborplace in Baltimore, announced on Thursday that it will lead the development of VIVA White Oak, a mixed use project planned for a 280-acre site in eastern Montgomery County, Maryland.

The land, near US 29 and Cherry Hill Road, is next to the U. S. Food and Drug Administration headquarters and near the Adventist HealthCare White Oak Medical Center. It’s also close to the University of Maryland’s College Park campus, the Interstate 95 corridor and BWI Thurgood Marshall International Airport. County officials have approved it for more than 12 million square feet of mixed-use development.

Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness

WASHINGTON, May 15, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. This Phase III study was conducted in real-world conditions on boats in the coastal waters of the United States (U.S.).

Maryland Stem Cell Research Commission Announces $15.4 Million in Awards to Accelerate Cures

48 scientists receive funding from the Maryland Stem Cell Research Fund to further research

COLUMBIA, Md. (May 14, 2024)—The Maryland Stem Cell Research Commission (“Commission”) is pleased to announce the next round of awards granting a total of more than $15.4 million. These awards are aimed at fostering groundbreaking research to enhance and propel stem cell treatments and technologies across Maryland.

Several esteemed scientists from various Maryland-based research institutions and companies have been selected as recipients in this grant cycle. Among the 48 distinguished awardees are academic researchers from prestigious institutions such as Johns Hopkins University; University of Maryland, Baltimore: University of Maryland, College Park; Lieber Institute for Brain Development; and the Hugo W. Moser Research Institute at Kennedy Krieger. Commercial sector entities like Seraxis Inc., Theradaptive, Inc., HOHCells, LLC, Agnos Therapeutics, Inc., and Reprocell U.S.A., Inc. were also awarded grants.

Gaithersburg's Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women

GAITHERSBURG, MD, May 20, 2024 (GLOBE NEWSWIRE) -- Amplexd Therapeutics, Inc. (“Amplexd” or the “Company”), a clinical stage patient-scientist-led biotech company specializing in accessible treatments for human papillomavirus (HPV)-induced Cervical Intraepithelial Neoplasia (CIN), is pleased to announce major updates in 2024 toward the finalization of product development ahead of Phase 1/2 clinical trials for its non-invasive treatments of CIN, the precursor to cervical cancer. The Company has secured US$2 Million for this initiative from an Asia-based life sciences focused family office. “The funding marks a major milestone in our R&D efforts for our two therapies after extremely promising preclinical studies were completed. The capital will enable us to finalize development and IND submissions ahead of first-in-human clinical trials, expected to commence later this year,” said Co-Founder and CEO Alia Rahman.

The strategic funding positions Amplexd Therapeutics to reshape the landscape in HPV and cervical precancer treatments with two topical, non-invasive options as potential alternatives to the “watch and wait” approach for low-grade CIN, and invasive surgery for high-grade CIN. Amplexd is poised to move the needle with the development of two low-cost therapies that favor patient comfort and increase access, and a vision to provide accessible solutions to target the often-overlooked public health crisis of HPV-induced cervical precancers.

Sands Capital’s Pulse Fund III Secures $555M Close

The Life Sciences Pulse strategy partners with private companies helping transform how diseases are defined, diagnosed, and treated.

Sands Capital is pleased to announce the close of our third life sciences fund, Sands Capital Life Sciences Pulse Fund III (“Pulse III”), raising $555 million. Pulse III was met with high demand from both existing and new limited partners. This close increases total Pulse strategy capital commitments to $1.3 billion, including Sands Capital Life Sciences Pulse Fund (“Pulse I”) and Sands Capital Life Sciences Pulse Fund II (“Pulse II”). The team will continue investing with the same emphasis on private therapeutics, diagnostics, medical devices, and life sciences tools businesses, in support of the strategy’s mission to help transform how diseases are defined, diagnosed, and treated.

“The life sciences sector continues to innovate at a rapid pace, leading to breakthroughs that benefit both patients and society as a whole,” said Stephen Zachary, Managing Partner. “We are grateful to both the investors joining us in Pulse III and the talented management teams we’ve partnered with since the strategy’s inception.”